Home - Products - Angiogenesis - EGFR - Dihydroberberine

Dihydroberberine

CAS No. 483-15-8

Dihydroberberine( —— )

Catalog No. M21509 CAS No. 483-15-8

Dihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	92	In Stock
10MG	163	In Stock
25MG	306	In Stock
50MG	423	In Stock
100MG	576	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Dihydroberberine
Note

Research use only, not for human use.
Brief Description

Dihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.
Description

Dihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Angiogenesis
Target

EGFR
Recptor

hERG| HSP90
Research Area

——
Indication

——

Chemical Information

CAS Number

483-15-8
Formula Weight

337.4
Molecular Formula

C20H19NO4
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 20 mg/mL (59.28 mM)
SMILES

COc(ccc1c2CN(CCc(c3c4)cc5c4OCO5)C3=C1)c2OC
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1.Yu D et al. Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells. PLoS One. 2017 Aug 1;12(8):e0181823.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Oritinib

Oritinib is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (d746-750), EGFR (d746-750/T790M), respectively. Oritinib can be used in studies about the treatment of non-small cell lung cancer.
Tyrphostin AG 112

Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.
CCF642

CCF642 is a novel PDI-inhibiting compound with antimyeloma activity.

Sign In Join Free